ⓘ Polatuzumab vedotin

                                     

ⓘ Polatuzumab vedotin

Polatuzumab vedotin is an antibody-drug conjugate or ADC designed for the treatment of cancer. The US Food and Drug Administration approved polatuzumab vedotin in June 2019 for treatment of diffuse large B-cell lymphoma when used in combination with bendamustine and rituximab. The drug was developed by Genentech and Roche.

Polatuzumab vedotin contains a humanized monoclonal antibody MAB targeting CD79b B-cell antigen receptor complex-associated protein beta-chain conjugated to a dolastatin analog nanometrovogo auristatin e MMAE via a protease-cleavable linker valine–citrulline, maleimidocaproylvaline-citrulline-p-aminobenzoyloxycarbonyl or MC-VC-PABC. The advantage of citrulline-valine VC linker is used that is highly stable in plasma.

                                     
  • Sofituzumab vedotin Polatuzumab vedotin RG7596 Enfortumab vedotin Pinatuzumab vedotin Lifastuzumab vedotin Brentuximab vedotin Glembatumumab vedotin Indusatumab
  • June 2010. It was re - introduced into the US market in 2017. Brentuximab vedotin trade name: Adcetris, marketed by Seattle Genetics and Millennium Takeda
  • influenza A and influenza B. Developed by Shionogi. 2019: Polivy Polatuzumab vedotin - piiq Treatment of diffuse large B - cell lymphoma when used in combination
  • Lumoxiti - Sept 2018 - CD22 Cemiplimab - Libtayo - Sept 2018 - PD - 1 Polatuzumab vedotin - Polivy - June 2019 - CD79B Recently, the bispecific antibodies
  • Perjeta pertuzumab for HER - 2 positive breast cancer. Polivy polatuzumab vedotin for diffuse large B - cell lymphoma. Protropin somatrem for growth